Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.
Paul G. Richardson, MD, clinical program leader and director for Clinical Research, Jerome Lipper Multiple Myeloma Center, institute physician at Dana-Farber Cancer Institute, and RJ Corman professor of Medicine at Harvard Medical School, discusses what is expected and exciting for the future of multiple myeloma research.
In the past few years, numerous therapies have been granted FDA approval for the treatment of patients with multiple myeloma, including belantamab mafodotin (Blenrep), melphalan flufenamide (Melflufen). Chimeric antigen receptor T-cell therapies consisting of idecabtagene vicleucel (ide-cel; Abecma), and ciltacabtagene autoleucel (cilta-cel; Carvykti) are also now FDA-approved, .
As experts work towards advancements in this space, Richardson explains that what he most looks forward to in regard to new approaches is the continued development of cellular therapies
Transcription:.
0:08 | In myeloma, which is my point focus, what really excites me is the continued development of cellular therapies until continued development of immune strategies that can overcome immune dysfunction in myeloma, which is important not only for the disease itself, but also for complications such as infection. As we think about new approaches, we have to be thinking about approaches that are real world, practical, deliverable, and take away from complicated intensive care, hospital type settings, and deliver care directly to our community practices so that they can be most effective in making an impact in the broader sense in the disease. That's an area of research, particularly given the pandemic, that has become very important.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More